Ibuprofen abuse potential should prevent monograph status -- McKenna & Cuneo.
IBUPROFEN ADVERSE EVENT REPORTING, SAFETY/EFFICACY RECOGNITION NEEDED, and therefore the drug should not be included in FDA's analgesic, antipyretic and antirheumatic drug products tentative final monograph, McKenna & Cuneo asserts in April 22 comments to the agency. The D.C. law firm opposes Whitehall-Robins Healthcare's citizen petition asking that ibuprofen (200 mg), which Whitehall sells as Advil, be added to the monograph as a single analgesic-antipyretic active ingredient. The American Home Products division filed the petition Nov. 28, citing the drug's 13-year marketing history and noting that monograph inclusion would "simplify the administrative burden" on both companies and FDA ("The Tan Sheet" Dec. 8, 1997, p. 4).
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Pink Sheet reporter and editors consider the issues that could emerge during upcoming private FDA forums with pharma CEOs, as well as the impact of the surprising move by HHS Secretary Robert F. Kennedy Jr. to limit the CDC recommendation for annual COVID-19 vaccine boosters.
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.